Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 4/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301121 | 0.81 | CDC7 (0.44) | CDC7SLC6A2ROCK1CYP19A1GLS | |
| SCHEMBL20357971 | 0.81 | CDC7 (0.81) | CDC7ROCK1CDK2 | |
| SCHEMBL3305437 | 0.80 | CDC7 (0.42) | CDC7SLC6A2CYP19A1GLS | |
| SCHEMBL3297325 | 0.79 | CDC7 (0.59) | CDC7SLC6A2ROCK1CDK2CYP19A1 | |
| SCHEMBL13391023 | 0.78 | CDC7 (0.54) | CDC7SLC6A2ROCK1 | |
| SCHEMBL20357894 | 0.77 | CDC7 (0.57) | CDC7SLC6A2ROCK1CDK2CYP19A1 | |
| SCHEMBL3304129 | 0.76 | CDC7 (0.56) | CDC7SLC6A2ROCK1CDK2CYP19A1 | |
| SCHEMBL20357974 | 0.75 | CDC7 (0.55) | CDC7SLC6A2ROCK1CDK2CYP19A1 | |
| SCHEMBL31735436 | 0.73 | CDC7 (0.52) | CDC7SLC6A2CYP19A1 | |
| SCHEMBL28670547 | 0.73 | CDC7 (0.52) | CDC7SLC6A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | CDC7 4322/4885SLC6A2 2503/4885ROCK1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.